Forecast

There is no analyst data available for this company.

News Go to news feed

Vitrolife: CEO Bronwyn Brophy O’Connor resigns

Vitrolife announces the resignation of CEO Bronwyn Brophy O’Connor, who is taking a CEO role in another area of medical technology. She will remain in office during a notice period of up to 12 months to ensure an orderly transition. The board of directors has begun the search for a successor and is considering internal and external candidates. » More on de.investing.com
Vitrolife: share rises despite missing Q1 expectations

Vitrolife reported Q1 2026 EPS of SEK 0.74 and revenue of SEK 807 million, both slightly below analyst expectations. Organic growth in local currency was 5%, while currency effects reduced reported revenue by 4%. Gross margin improved to 59.9% and EBITDA rose 4.6%, supported by higher‑margin products and growth in the Americas and APAC. Despite the figures, the stock climbed 6.97% in pre‑market trading, supported by a robust product pipeline and planned product launches. » More on de.investing.com
Vitrolife raises gross margin to 59.9% despite slightly lower sales in Q1 2026

Vitrolife reported Q1 2026 sales of SEK 807m (–4% reported, +5% organic) and a gross margin of 59.9% thanks to a product-mix shift. EBITDA was SEK 251m (margin 31.1%), earnings per share were SEK 0.74, slightly below consensus. The Americas grew organically by 11%, APAC recovered by 7%, while EMEA was weighed down by the crisis in the Middle East. Operating cash flow rose strongly to SEK 172m, the dividend is to remain SEK 1.10, and management expects further margin improvements from restructuring and product launches. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Vitrolife AB has already paid 0,10€ in dividends. The last payout was in May.

Financials

In the last quarter, Vitrolife AB had revenue of 77,33M€ and net profit of 11,64M€

(EUR)	Jun 2026	YoY
Revenue	+77,33M	1,07%
Gross profit	+46,65M	2,94%
Net profit	+11,64M	29,71%
EBITDA	+23,28M	6,75%

Fundamentals

Metric	Value
Market capitalization	+1,16Mld€
Number of shares	135,42M
52-week high/low	+13,84€ - +7,58€
Dividend yield	+1,16%
Dividends TTM	+0,10€
Beta	1,71
P/E ratio	−2,58
PEG ratio	0,00
P/B ratio	+1,58
P/S ratio	+3,80

Company profile

Vitrolife AB (publ), ein Medizintechnikunternehmen, entwickelt, produziert und vermarktet Produkte für die assistierte Reproduktion. Das Unternehmen bietet Nadeln zur Eizellentnahme, Spermienaufbereitung, Medien und Öle für die In-vitro-Fertilisation, Mikromanipulationspipetten, Laborgeräte, Inkubatoren, Kryokonservierung und Produkte für genetische Präimplantationstests. Das Unternehmen bietet auch EmbryoScope und Primo Vision Zeitraffersysteme, Zeitrafferschalen, Auswertungswerkzeuge für Zeitraffersysteme und Octax Laser- und Bildgebungssysteme sowie Log- und Wächtersysteme und drahtlose Sensoren an. Das Unternehmen ist in Europa, dem Nahen Osten und Afrika, Asien, Japan und dem Pazifikraum sowie in Nord- und Südamerika tätig. Das Unternehmen war früher unter dem Namen Scandinavian IVF Science bekannt und änderte 1998 seinen Namen in Vitrolife AB (publ). Vitrolife AB (publ) wurde 1994 gegründet und hat seinen Hauptsitz in Göteborg, Schweden.

Name	Vitrolife AB
CEO	Bronwyn Brophy O'Connor
Headquarters	Gothenburg, vg Sweden
Website	vitrolife.com
Sector	Health Care
Industry	Health Care Equipment & Supplies
IPO	09/01/2023
Employees	1.103